Financhill
Buy
54

ACLX Quote, Financials, Valuation and Earnings

Last price:
$66.03
Seasonality move :
1.31%
Day range:
$64.90 - $66.67
52-week range:
$47.86 - $107.37
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
46.56x
P/B ratio:
8.72x
Volume:
514.5K
Avg. volume:
894.8K
1-year change:
18.3%
Market cap:
$3.6B
Revenue:
$107.9M
EPS (TTM):
-$2.99

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ACLX
Arcellx
$19.5M -$0.74 -53% -107.65% $111.21
AKYA
Akoya Biosciences
$19.3M -$0.23 -21.86% -14.82% $1.42
NBY
NovaBay Pharmaceuticals
$3M -$0.88 14.03% -95.43% $0.85
OGEN
Oragenics
-- -- -- -- $1.00
QTRX
Quanterix
$28.3M -$0.69 -10.47% -- $11.25
TOVX
Theriva Biologics
-- -$1.56 -- -95.63% $7.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ACLX
Arcellx
$66.00 $111.21 $3.6B -- $0.00 0% 46.56x
AKYA
Akoya Biosciences
$1.23 $1.42 $61.3M -- $0.00 0% 0.76x
NBY
NovaBay Pharmaceuticals
$0.60 $0.85 $3.5M -- $0.00 0% 0.16x
OGEN
Oragenics
$4.36 $1.00 $3.1M -- $0.00 0% 1.40x
QTRX
Quanterix
$6.06 $11.25 $235.3M -- $0.00 0% 1.74x
TOVX
Theriva Biologics
$0.50 $7.00 $4.1M -- $0.00 0% 0.33x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ACLX
Arcellx
-- 0.617 -- 4.83x
AKYA
Akoya Biosciences
108.34% 1.564 110.41% 0.36x
NBY
NovaBay Pharmaceuticals
4.54% -0.941 1.51% 0.75x
OGEN
Oragenics
-- -1.150 -- --
QTRX
Quanterix
-- 0.311 -- 7.31x
TOVX
Theriva Biologics
-- -3.651 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ACLX
Arcellx
-- -$68.9M -34.73% -34.73% -765.88% -$63.9M
AKYA
Akoya Biosciences
$9.9M -$13.3M -52.81% -338.02% -78.8% -$7.4M
NBY
NovaBay Pharmaceuticals
$1.6M -$2.7M -334.47% -461.38% -44% -$1.3M
OGEN
Oragenics
-- -$2M -- -- -- -$2.1M
QTRX
Quanterix
$16.4M -$26.4M -14.39% -14.39% -87.09% -$15.1M
TOVX
Theriva Biologics
-- -$4.4M -- -- -- -$4.8M

Arcellx vs. Competitors

  • Which has Higher Returns ACLX or AKYA?

    Akoya Biosciences has a net margin of -766.02% compared to Arcellx's net margin of -94.07%. Arcellx's return on equity of -34.73% beat Akoya Biosciences's return on equity of -338.02%.

    Company Gross Margin Earnings Per Share Invested Capital
    ACLX
    Arcellx
    -- -$1.13 $416.9M
    AKYA
    Akoya Biosciences
    59.33% -$0.32 $70.6M
  • What do Analysts Say About ACLX or AKYA?

    Arcellx has a consensus price target of $111.21, signalling upside risk potential of 68.51%. On the other hand Akoya Biosciences has an analysts' consensus of $1.42 which suggests that it could grow by 15.24%. Given that Arcellx has higher upside potential than Akoya Biosciences, analysts believe Arcellx is more attractive than Akoya Biosciences.

    Company Buy Ratings Hold Ratings Sell Ratings
    ACLX
    Arcellx
    11 0 0
    AKYA
    Akoya Biosciences
    0 7 0
  • Is ACLX or AKYA More Risky?

    Arcellx has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Akoya Biosciences has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock ACLX or AKYA?

    Arcellx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Akoya Biosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcellx pays -- of its earnings as a dividend. Akoya Biosciences pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ACLX or AKYA?

    Arcellx quarterly revenues are $8.1M, which are smaller than Akoya Biosciences quarterly revenues of $16.6M. Arcellx's net income of -$62.3M is lower than Akoya Biosciences's net income of -$15.7M. Notably, Arcellx's price-to-earnings ratio is -- while Akoya Biosciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcellx is 46.56x versus 0.76x for Akoya Biosciences. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ACLX
    Arcellx
    46.56x -- $8.1M -$62.3M
    AKYA
    Akoya Biosciences
    0.76x -- $16.6M -$15.7M
  • Which has Higher Returns ACLX or NBY?

    NovaBay Pharmaceuticals has a net margin of -766.02% compared to Arcellx's net margin of -49.65%. Arcellx's return on equity of -34.73% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    ACLX
    Arcellx
    -- -$1.13 $416.9M
    NBY
    NovaBay Pharmaceuticals
    65.26% $1.42 $1.1M
  • What do Analysts Say About ACLX or NBY?

    Arcellx has a consensus price target of $111.21, signalling upside risk potential of 68.51%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 41.67%. Given that Arcellx has higher upside potential than NovaBay Pharmaceuticals, analysts believe Arcellx is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    ACLX
    Arcellx
    11 0 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is ACLX or NBY More Risky?

    Arcellx has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.305%.

  • Which is a Better Dividend Stock ACLX or NBY?

    Arcellx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcellx pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ACLX or NBY?

    Arcellx quarterly revenues are $8.1M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Arcellx's net income of -$62.3M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Arcellx's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcellx is 46.56x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ACLX
    Arcellx
    46.56x -- $8.1M -$62.3M
    NBY
    NovaBay Pharmaceuticals
    0.16x -- $2.4M $7.7M
  • Which has Higher Returns ACLX or OGEN?

    Oragenics has a net margin of -766.02% compared to Arcellx's net margin of --. Arcellx's return on equity of -34.73% beat Oragenics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ACLX
    Arcellx
    -- -$1.13 $416.9M
    OGEN
    Oragenics
    -- -$3.60 --
  • What do Analysts Say About ACLX or OGEN?

    Arcellx has a consensus price target of $111.21, signalling upside risk potential of 68.51%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 588.14%. Given that Oragenics has higher upside potential than Arcellx, analysts believe Oragenics is more attractive than Arcellx.

    Company Buy Ratings Hold Ratings Sell Ratings
    ACLX
    Arcellx
    11 0 0
    OGEN
    Oragenics
    0 1 0
  • Is ACLX or OGEN More Risky?

    Arcellx has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oragenics has a beta of 0.938, suggesting its less volatile than the S&P 500 by 6.243%.

  • Which is a Better Dividend Stock ACLX or OGEN?

    Arcellx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcellx pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ACLX or OGEN?

    Arcellx quarterly revenues are $8.1M, which are larger than Oragenics quarterly revenues of --. Arcellx's net income of -$62.3M is lower than Oragenics's net income of -$2.2M. Notably, Arcellx's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcellx is 46.56x versus 1.40x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ACLX
    Arcellx
    46.56x -- $8.1M -$62.3M
    OGEN
    Oragenics
    1.40x -- -- -$2.2M
  • Which has Higher Returns ACLX or QTRX?

    Quanterix has a net margin of -766.02% compared to Arcellx's net margin of -67.73%. Arcellx's return on equity of -34.73% beat Quanterix's return on equity of -14.39%.

    Company Gross Margin Earnings Per Share Invested Capital
    ACLX
    Arcellx
    -- -$1.13 $416.9M
    QTRX
    Quanterix
    54.03% -$0.53 $316.4M
  • What do Analysts Say About ACLX or QTRX?

    Arcellx has a consensus price target of $111.21, signalling upside risk potential of 68.51%. On the other hand Quanterix has an analysts' consensus of $11.25 which suggests that it could grow by 85.64%. Given that Quanterix has higher upside potential than Arcellx, analysts believe Quanterix is more attractive than Arcellx.

    Company Buy Ratings Hold Ratings Sell Ratings
    ACLX
    Arcellx
    11 0 0
    QTRX
    Quanterix
    1 2 0
  • Is ACLX or QTRX More Risky?

    Arcellx has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Quanterix has a beta of 1.055, suggesting its more volatile than the S&P 500 by 5.534%.

  • Which is a Better Dividend Stock ACLX or QTRX?

    Arcellx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quanterix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcellx pays -- of its earnings as a dividend. Quanterix pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ACLX or QTRX?

    Arcellx quarterly revenues are $8.1M, which are smaller than Quanterix quarterly revenues of $30.3M. Arcellx's net income of -$62.3M is lower than Quanterix's net income of -$20.5M. Notably, Arcellx's price-to-earnings ratio is -- while Quanterix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcellx is 46.56x versus 1.74x for Quanterix. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ACLX
    Arcellx
    46.56x -- $8.1M -$62.3M
    QTRX
    Quanterix
    1.74x -- $30.3M -$20.5M
  • Which has Higher Returns ACLX or TOVX?

    Theriva Biologics has a net margin of -766.02% compared to Arcellx's net margin of --. Arcellx's return on equity of -34.73% beat Theriva Biologics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ACLX
    Arcellx
    -- -$1.13 $416.9M
    TOVX
    Theriva Biologics
    -- -$1.55 --
  • What do Analysts Say About ACLX or TOVX?

    Arcellx has a consensus price target of $111.21, signalling upside risk potential of 68.51%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1301.12%. Given that Theriva Biologics has higher upside potential than Arcellx, analysts believe Theriva Biologics is more attractive than Arcellx.

    Company Buy Ratings Hold Ratings Sell Ratings
    ACLX
    Arcellx
    11 0 0
    TOVX
    Theriva Biologics
    1 1 0
  • Is ACLX or TOVX More Risky?

    Arcellx has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.848, suggesting its less volatile than the S&P 500 by 15.165%.

  • Which is a Better Dividend Stock ACLX or TOVX?

    Arcellx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcellx pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ACLX or TOVX?

    Arcellx quarterly revenues are $8.1M, which are larger than Theriva Biologics quarterly revenues of --. Arcellx's net income of -$62.3M is lower than Theriva Biologics's net income of -$4.3M. Notably, Arcellx's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcellx is 46.56x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ACLX
    Arcellx
    46.56x -- $8.1M -$62.3M
    TOVX
    Theriva Biologics
    0.33x -- -- -$4.3M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

How High Will Roku Stock Go?
How High Will Roku Stock Go?

Streaming software and hardware maker Roku (NASDAQ:ROKU) has seen its…

Where Will The Trade Desk’s Stock Be in 5 Years?
Where Will The Trade Desk’s Stock Be in 5 Years?

If you stitched together every advertisement The Trade Desk (NASDAQ:…

Is MSTR Stock Fundamentally Misunderstood?
Is MSTR Stock Fundamentally Misunderstood?

Software firm turned Bitcoin treasury Strategy (NASDAQ:MSTR) has made waves…

Stock Ideas

Buy
65
Is MSFT Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 40x

Buy
57
Is NVDA Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 48x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 32x

Alerts

Sell
11
VEON alert for Jun 14

VEON [VEON] is down 18.57% over the past day.

Buy
74
DAVE alert for Jun 14

Dave [DAVE] is down 12.68% over the past day.

Buy
54
DAR alert for Jun 14

Darling Ingredients [DAR] is up 9.12% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock